NRX Pharmaceuticals, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $11.9M | $32.7M | $27.6M |
| FY2022 | $18.4M | $25.8M | $20.1M |
| FY2023 | $19.0M | $7.3M | $4.6M |
| FY2024 | $26.9M | $3.7M | $1.4M |
| FY2025 | $28.9M | $13.0M | $7.8M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $11.9M | $32.7M | $27.6M |
| FY2022 | $18.4M | $25.8M | $20.1M |
| FY2023 | $19.0M | $7.3M | $4.6M |
| FY2024 | $26.9M | $3.7M | $1.4M |
| FY2025 | $28.9M | $13.0M | $7.8M |